Product Description
Mechanisms of Action: FIX Analogue
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Colombia | Croatia | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Indonesia | Italy | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Spain | Taiwan | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hemophilia B|Hemophilia A
Phase 2: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
FMTN-II-GIST | P2 |
Not yet recruiting |
Multiple Myeloma |
2022-08-01 |
|
2020-004430-38 | P4 |
Active, not recruiting |
Hemophilia B |
2021-03-19 |
|
B1821059 | P4 |
Completed |
Hemophilia A|Hemophilia B |
2020-09-24 |
|
2014-004156-65 | P3 |
Active, not recruiting |
Hemophilia B |
2019-06-06 |